|
Emerging AI-Driven Biotech Sybleu, Inc. (OTC:SYBE) offers competitive advantages and upcoming milestones in the stock market's top-followed and funded segment, AI, prompting a potential surge in the stock ...
... of pediatric patients. Unlike drug and surgical device therapies, IB-Stim™ is non-drug, non-surgical that can be placed in patients in an outpatient clinic. The device is worn for 120 hours per week for ...
... innovative assay measures tumor stemness, which can predict the risk of treatment resistance or distant recurrence in cancer patients. Moreover, the assay is best suited to identify the ideal type of surgery ...
... Ocular Surface and TVST, section editor for Eye and assistant editor at Ocular Immunology and Inflammation.
Jay S. Pepose, MD, PhD, FARVO
Dr. Pepose, a specialist in refractive surgery and corneal ...
... of innovative biological products and proprietary technologies for bone growth in surgical spine procedures and advanced autologous cell therapies for regenerating cartilage in joints and spinal discs. ...
... of innovative biological products and proprietary technologies for bone growth in surgical spine procedures and advanced autologous cell therapies for regenerating cartilage in joints and spinal discs. ...
... the Company has made significant progress since our initial report in January 2021. There has been a huge surge in the use of radiopharmaceuticals for the diagnosis and treatment of chronic diseases, ...
... in $1.5 billion a day into the market, that answered the question that was plaguing me/ Why were stocks performing so well across the board? It may have also played an early role in the crypto resurgence. ...
... in a more favorable environment, given the surge in US consumer gun ownership. Couple this growth with opportunities in military and law enforcement at home and abroad and it appears that the core business ...
... surgical veterinary practices. While both administration of PETV’s therapy and HA injections may involve sedation of the animal, joint replacement involves invasive surgery and rehabilitation. As such ...
... a resurgence in this line item in 2021 and 2022.
…a potentially stronger 2021
Looking ahead, we forecast revenue will grow by 48.7% to $34.5M and EPS of $1.08 in 2021 As illustrated ...
... rise, led by its existing channels, a resurgence in YouTuber/Gamer-generated sales, and expansion of both products and geographies, including CBD sales, which we view as a sleeper---especially as new ...
... was spent on pets in the U.S. with the figure expected to grow to $99 billion in 2020. We believe, however, that this 2020 figure could be low. Since the onset of the COVID-19 pandemic, a surge in pet ...
... surgical procedures. Perhaps no category is as ripe for migration to an alternative therapy such as bioelectronics as opioids.
Many patients are not initially aware of the highly addictive properties ...
... use of radiopharmaceutical therapy (RPT). There has been a significant surge in the use of radiopharmaceuticals for the diagnosis and treatment of chronic diseases, with the market expected to reach ...
... toxic painkillers (such as opioids) and invasive surgical procedures. Perhaps no category is as ripe for migration to an alternative therapy such as bioelectronics as opioids.
Many patients are not ...
... PETV biomaterial in combination with other materials in a surgical setting a veterinary clinic can provide great medical benefit by helping to promote neovascularization and could enhance tissue healing ...
... however, that this 2020 figure could be low. Since the onset of the COVID-19 pandemic, a surge in pet ownership has occurred with some shelters and rescues devoid of any adoptable pets at all, due to skyrocketing ...
With Surge Holdings (OTC -SURG) set to enjoy a 300% increase in revenue to $100M+ in 2020, we have raised our forecasts and price target.
Investment and Company Research Opportunity Research ...
Surge Holdings (OTC -SURG) is poised to generate outsized revenue and market share due to major acquisition, innovative model, and CBD positioning.
Investment and Company Research Opportunity ...
... are just beginning to be sated. Since we are in the early innings of this discovery-to-development cycle of gold by the juniors—often in new locales, resurgence is now underway as many firms exit the ...
Surge Holdings (OTC -SURG) is poised to generate outsized revenue and market share in large, underserved markets.
Investment and Company Research Opportunity Research COMPANY REPORT
...
... a resurgence in interest in the space. Still, the Company’s low-cost/high return approach in its fast-growing niche should serve it well. Moreover, the industry is in the early innings of growth, ...
... high for a particular optic nerve, whatever that pressure measurement may be, glaucoma will develop.”
The AOI notes that while current therapies (medications, surgeries including fluid drainage) ...
Surge Holdings (OTC - SURG) is adding stores, new SaaS portals, and new offerings which should all translate to huge growth next year.
Investment and Company Research Opportunity Research ...
...
The AURACIS technology was originally developed by Dr. Ioannis Skaribas, MD a Houston, Texas board-certified anesthesiologist and pain surgeon. Dr. Skaribas has treated thousands of severe migraine ...
... treatments for patients with gastrointestinal (GI) disorders. The company’s first product, Regentys Extra-Cellular Matrix Hydrogel (RECMH), is a first-in-class, non-pharmacologic, non-surgical ...
Recent sell-off in LandStar (OTC - LDSR) appears to be buy on rumor sell on news. Thanksgiving week schedule may also prove to be in LDSR's favor.
Investment and Company Research Opportunity ...
... is the major valuation driver for the Company, at present. The Veneto Group provides specialty pharmacy services and products including surgical products and services, diagnostic testing for screening ...
Surge Holdings: Strong Q2 with 20% growth, $1.6M in cash, yet a low valuation---but not for long.
Surge Holdings: Strong Q2 with 20% growth, $1.6M in cash, yet a low valuation---but not for long. ...
This overlooked, underfollowed company targeting overlooked, underserved customers and businesses offers unmatched upside
This overlooked, underfollowed company targeting overlooked, underserved ...
... we are in the early innings of this discovery-to-development cycle of gold by the juniors—often in new locales, resurgence is now underway as many firms exit the pre-discovery phase and enter the profitable ...
... the Indians’ first baseman, Mike Napoli, underwent surgery to correct sleep apnea a year ago. A common problem that many people ignore, but we digress…
Speaking of rest and relaxation, La-Z-Boy Incorporated ...
... life science research. The Company offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical ...
... surgical scalpels for example, selling for up to $3000 per carat. At a cost of a few hundred thousand dollars per machine, and with the throughput noted above, it is easy to see that Centaurus can very ...
... since it trades with a 12-month forward P/E of 18.1x, the homebuilding sector, which seems to be enjoying a bit of a resurgence in 2016, trades at a paltry 11.9x.
After its Q1 beating, the biotechnology ...
... implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 500,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ...
... hikes, combined with rotten earnings plagued us for six weeks.
Magically, about a month ago, oil began to rise, the dollar fell, commodities surged, earnings forecasts were not so bad, cries that ...
... use in cardiac and vascular surgeries. The Company operates in two segments, Medical Devices and Preservation Services. It offers surgical sealants and hemostats, including BioGlue Surgical Adhesive, a ...
... resurgence and M&A activity will return, in spurts, especially in the lower end of the market.
Prediction #4: Tech and health care will continue to find fans and deliver winners while consumer ...
Look, there is a reason gun sales are surging and the more gun control advocates make noise or these horrific events occur, the more gun sales will climb. Thus, it is a no-brainer town these stocks, ...
... Operating Officer of Eminent Technology Partners and Chief Executive Office of its subsidiary, Eminent Research Systems, Vice President and General Manager, Vascular Therapies, for U.S. Surgical Corporation ...
... Fitbit Surge, a fitness watch that consists of GPS watch, heart rate tracker, activity tracker, and smartwatch; and Fitbit Aria, a Wi-Fi connected scale that tracks weight, body fat percentage, and body ...
... pancreatic cancer patients as survival rates from this disease are consistently the lowest of all solid tumors. Today, the surgical removal of pancreatic cancer tumors followed by chemotherapy tends ...
... spending money on major surgery, acupuncture and other exotic procedures to keep Fido around. Sometimes you have to wonder if it has gone too far. Surely anyone who has turned on a TV over the last week ...
As expected, stocks are surging higher due in part to low gas prices. However, the current rise cannot go on forever. We believe we have identified what could temporarily curtail stocks as well as when ...
... that the Company's Start Fresh Program® used by the clinics above already includes an outpatient surgical implantation of Naltrexone in combination with the Company's life coaching program in order to ...
... marketed and ever-important Cyber Monday where consumers are sure to find great holiday deals online.
The period from Thanksgiving Week through year-end is usually highlighted by a resurgence ...
... in price, is usually an indicator of surging economic activity. Copper, the commodity, is down over 6% this year, and has bounced between $3 to $4 per pound over the last three years. A breakthrough to ...
... bearish trend.
Stock Resurgence?
The chart to the left certainly is not pretty. But, the recent trading stats may make you feel better.
Right now, we are in the middle of the 52-week range ...
|
||
|
|
||